What result or caveat matters most to you?
What happened
Response-tailored therapy adds 13 days alive without antibiotics vs standard care in left-sided infective endocarditis.
What result or caveat matters most to you?
Therapy dropped from 41 to 26 days with similar safety, but more relapses mean careful selection and follow-up are essential.
X post ↗Tailored antibiotics won on days off treatment and held up on safety, but higher relapse means shorter isn't free.
X post ↗Current recommendations of up to six weeks are based mostly on historical observations from the 1950s when lower doses of antibiotic monotherapy were used. We hypothesized that tailoring antibiotic therapy in those who have an initial positive response could safely reduce the duration of antibiotics.
POET-II co-authorThe results from our landmark trial have the potential to change clinical practice. We estimate that around half of the patients that we see in our clinics with left-sided infective endocarditis could be eligible for tailored reduced-duration antibiotic therapy. Shorter courses of antibiotics may also improve patients' quality of life by reducing the physical and psychological toll associated with prolonged antibiotic treatment and hospitalisations.
POET-II co-authorESC Congress 2026 · Hot Line 1 (Fri 28 Aug) — 3 trials now in the register: POET-II, ACACIA-HCM, CMR GUIDE 🧵 #ESCCongress #EBM
t.cot.coPOET-IIPOET-II suggests that in carefully selected, clinically stable left-sided infective endocarditis, response-tailored antibiotic therapy can shorten treatment by about 2 weeks while maintaining non-inferior composite safety. #POETII #ESC2026
t.coPOET-IIGeneral · Cedars-Sinai Medical Center
#POETII at #ESCCongress Do all patients with left-sided infective #endocarditis really need 4–6 weeks of antibiotics? 508 patients randomized ⏱️ 6-month follow-up Tailored: 2–4 w 🆚Standard: 4–6 w 🫀Tailored treatment substantially ⤵️antibiotic exposure: ➡️ 27 vs 42 days — 15
t.coPOET-IIInterventional Cardiology
Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis: @NEJM #ESCCongress2026 🥸POET II trial: Response Tailored vs Standard Duration Therapy 😱 Take a look below: 👇👇👇
t.coPOET-II1/3 POET-II — In 508 patients with left-sided infective endocarditis, a tailored 2–4-week antibiotic course was non-inferior to the standard 4–6-week course for death, unplanned cardiac surgery, relapse or embolisation at 6 months.
t.cot.coPOET-IIInterventional Cardiology
🥸 1️⃣ The recommendation of up to 6 weeks of antibiotic therapy for infective endocarditis on the left side of the heart rests largely on expert opinion and historical observation rather than randomized evidence. - The POET II trial tested a shorter, response tailored strategy
POET-II🆕🔥🔥POET II RCT NEJM Among patients with infective endocarditis on the left side of the heart, the use of a response-tailored antibiotic strategy* resulted in a longer time alive without antibiotic therapy than standard-duration therapy and met the criterion for noninferiority
t.coPOET-IIPOET II at #ESCCongress: can we safely shorten antibiotic treatment for infective endocarditis? The original POET trial changed practice by showing that selected, clinically stable patients with left-sided infective endocarditis could complete treatment with oral rather than
t.coPOET-IIOpen questions from this trial that would benefit from expert input.
Answers are grounded in this paper and cite their sources.
Why the trial, tables, limitations, PICO, abstract, media & sources
Left-sided infective endocarditis is treated with fixed 4-6 week antibiotic courses set by convention rather than individual response. Whether tailoring treatment duration to each patient's clinical and microbiological response can reduce antibiotic exposure without compromising safety had not been tested in a randomised trial.
Does response-tailored antibiotic therapy improve days alive without antibiotics and maintain safety compared to standard-duration therapy in patients with left-sided infective endocarditis?
| Outcome | Tailored | Standard |
|---|---|---|
| Median days alive without antibiotics Difference 13 days (95% CI 12-13); P<0.001 for superiority | Tailored 183 | Standard 169 |
| Relapse of bacteremia or endocarditis Key secondary - higher with tailored therapy (P=0.04); opposite direction from the efficacy gain | Tailored 13 (5.1%) | Standard 4 (1.6%) |
Does response-tailored antibiotic therapy improve days alive without antibiotics and maintain safety compared to standard-duration therapy in patients with left-sided infective endocarditis?
In stable patients with left-sided infective endocarditis, a response-tailored antibiotic strategy shortened treatment duration and was noninferior for safety, but increased the risk of relapse.
Experts see tailoring antibiotic length to treatment response as a credible way to shorten therapy for stable left-sided endocarditis, but they flag the higher relapse rate as a real cost that calls for careful patient selection.
The trial's lead investigator says the result could change practice and that many patients with left-sided endocarditis may qualify for shorter courses. Other cardiologists accept that shorter therapy held up on safety, but they stress that relapse was more common. The open question is how to pick the patients who can safely stop early and how closely to follow them afterward.
Two cardiologists agree that the shorter, response-tailored approach came with more relapses than standard therapy. In their view, shortening treatment has a cost, so selection and follow-up matter.
What they’re arguing about
supportiveneutralcautiouscritical
Counts are expert takes we classified by axis. Tap a row to see the takes behind its count.
Experts point to the higher relapse rate but do not say which patients carry that risk. They also do not say how follow-up should be set up to catch relapse early.
Supports response-tailored shorter antibiotics in left-sided IE with noninferior safety; extends RCT evidence but requires relapse monitoring.
BACKGROUND: In patients with infective endocarditis on the left side of the heart, the current recommendation of up to 6 weeks of antibiotic therapy is based largely on expert consensus opinion. Whether a clinical response-tailored antibiotic management strategy can shorten treatment duration without compromising safety is unclear. Before randomization, all the patients received at least the prespecified 2 to 4 weeks of therapy and met criteria for clinical stabilization. After randomization, patients in the tailored-therapy group discontinued antibiotics and those in the standard-therapy group continued standard treatment (total duration, 4 to 6 weeks). The primary efficacy end point was days alive without antibiotic treatment for infective endocarditis or bacteremia within 6 months after randomization (tested for superiority). The primary safety end point was a composite of death from any cause, unplanned cardiac surgery, or symptomatic embolic events within 6 months after randomization (tested for noninferiority; margin, 7.5 percentage points). Relapse of bacteremia or infective endocarditis was a key secondary end point. RESULTS: A total of 508 patients underwent randomization, with 255 assigned to response-tailored therapy and 253 to standard-duration therapy. The median time alive without antibiotic treatment was 183 days (interquartile range, 181 to 183) with tailored therapy and 169 days (interquartile range, 166 to 171) with standard therapy (Hodges-Lehmann estimated difference, 13 days; 95% confidence interval [CI], 12 to 13; P<0.001 for superiority). A primary safety end-point event occurred in 21 patients (8.2%) with tailored therapy and in 27 patients (10.7%) with standard therapy (absolute between-group difference, -2.4 percentage points; 95% CI, -7.7 to 2.7; P<0.001 for noninferiority), indicating noninferiority. Relapse occurred in 13 patients (5.1%) with tailored therapy and in 4 patients (1.6%) with standard therapy (P = 0.04). CONCLUSIONS: Among patients with infective endocarditis on the left side of the heart, the use of a response-tailored antibiotic strategy resulted in a longer time alive without antibiotic therapy than standard-duration therapy and met the criterion for noninferiority with respect to safety but was associated with a higher incidence of relapse of bacteremia or infective endocarditis. (Funded by Sygeforsikringen "danmark" and others; POET II ClinicalTrials.gov number, NCT03851575.).
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Bundgaard et al. (2026) conducted an RCT in Infective endocarditis on the left side of the heart (n=508). Response-tailored antibiotic therapy vs. Standard-duration antibiotic therapy was evaluated on Days alive without antibiotic treatment for infective endocarditis or bacteremia within 6 months (Hodges-Lehmann estimated difference 13 days, 95% CI 12 to 13, p=<0.001 for superiority). Response-tailored antibiotic therapy increased days alive without antibiotics (difference 13 days) and was noninferior to standard therapy for safety, but increased relapse.
Synapse has enriched 10 related papers. Consider them for comparative context: